Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma

Phase 2 Unknown 50 enrolled Sun Yat-sen University

NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to modified BFM-95 regimen for acute lymphoblastic leukemia.

Timeline

Start: 2015-03
Primary completion: 2025-03
Completion: 2025-03

Publications

Results Wang K, Chen X, Wuxiao Z, Wang Z, Sun X, Zeng Z, Li S, Xia ZJ. Long-term outcomes of modified Berlin-Frankfurt-Munster-90 regimen in adults with T-lymphoblastic lymphoma: a single-center experience. Leuk Lymphoma. 2014 Aug;55(8):1800-5. doi: 10.3109/10428194.2013.828350. Epub 2014 Mar 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	1000 mg/m2	Intravenous
Subject	Cytarabine	Small molecule	40 mg/m2	Intravenous
Subject	Cytarabine	Small molecule	75 mg/m2	Intravenous
Subject	Dexamethasone	Small molecule	4 mg	Intrathecal
Subject	MERCAPTOPURINE ANHYDROUS	Small molecule	25 mg/m2	Oral
Subject	MERCAPTOPURINE ANHYDROUS	Small molecule	50 mg/m2	Oral
Subject	MERCAPTOPURINE ANHYDROUS	Small molecule	60 mg/m2	Oral
Subject	Methotrexate	Small molecule	15 mg/m2	Oral
Subject	Methotrexate	Small molecule	20 mg/m2	Oral
Subject	Methotrexate	Small molecule	5 g	Oral
Subject	Pegaspargase	Protein / enzyme biologic	3750 unknown	Intramuscular
Subject	Pirarubicin	Small molecule	30 mg/m2	Intravenous
Subject	Prednisone	Other / unclassified	60 mg/m2	Oral
Subject	Vincristine	Small molecule	1.5 mg/m2	Intravenous

Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma

Summary

Timeline

Publications

Drugs

Indications